Navigation Links
Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

ich are usually transient.  Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia and hypernatremia. Nausea and vomiting have been reported. Use with caution in diabetics. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing information, visit www.kristalose.com.

Forward-Looking StatementsThis press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's Form 10-K filed with the SEC on March 11, 2011. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIESCondensed Consolidated Balance Sheets(Unaudited)September 30,December 31,20112010ASSETSCurrent assets:Cash
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
2. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
3. Cumberland Pharmaceuticals Appoints Lee Product Director
4. Cumberland Emerging Technologies and UT Research Foundation Sign License Agreement for New Technology
5. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
6. Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM)
7. Cumberland Pharmaceuticals Announces Pricing of Its Initial Public Offering of Common Stock
8. Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
10. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
11. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Chicago, IL (PRWEB) November 21, 2014 ... technology competitors at the 2014 Emerging Medical Technologies Summit ... MedTech Innovator Awards. Widely regarded among Silicon Valley ... emerging medical device innovation, the win also positions Briteseed ... the MedTech Innovator competition in 2015 and compete with ...
(Date:11/22/2014)... Rapids, MI (PRWEB) November 22, 2014 ... opportunity to simulate the proper management of life-like ... and test lung devices . Grand Rapids-based, Michigan ... plans to donate two of the respiratory simulation ... to $15,000 each. Grand Valley and Muskegon Community ...
(Date:11/22/2014)... , November 21, 2014 ... wechselt als Chief Commercial Officer zu KLOX    ... der Unternehmensentwicklung und Chief Financial Officer bestellt    ... mit der Vermarktung seines jüngst zugelassenen Behandlungssystems zur Wundheilung ... ("KLOX" bzw. das "Unternehmen") ist sehr erfreut, die folgenden ...
(Date:11/21/2014)... --  TRU-D SmartUVC LLC and its UK partners, Rapid ... robot, TRU-D SmartUVC, at FIS 2014 in Harrogate, ... at Stand 23. The conference, hosted by Federation ... largest infection-related event of its kind and brings together ... leading events of its type throughout the world. This annual ...
Breaking Biology Technology:Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3
... ... with the Gwendolyn Strong Foundation on a fundraising campaign for spinal muscular atrophy gene ... (PRWEB) ... for SMA gene therapy, “Realizing the Dream.” FightSMA is collaborating with the Santa ...
... CHICAGO , July 8 Advanced Life Sciences Holdings, ... discovery, development and commercialization of novel drugs in the therapeutic areas ... preclinical toxicology and pharmacokinetic studies of an intravenous (IV) formulation of ... setting. , , , ...
... SAN FRANCISCO , July 7 The Real Staffing Group, a ... launched new offices in New York and San Francisco . ... this occasion by launching a new app for the iPhone. This app provides ... and Europe . , , ...
Cached Biology Technology:FightSMA Launches Gene Therapy Fundraising Campaign: “Realizing the Dream” 2FightSMA Launches Gene Therapy Fundraising Campaign: “Realizing the Dream” 3FightSMA Launches Gene Therapy Fundraising Campaign: “Realizing the Dream” 4Advanced Life Sciences Announces Successful Preclinical Data Supporting Restanza Intravenous Formulation for Hospital Use 2Advanced Life Sciences Announces Successful Preclinical Data Supporting Restanza Intravenous Formulation for Hospital Use 3Advanced Life Sciences Announces Successful Preclinical Data Supporting Restanza Intravenous Formulation for Hospital Use 4A Real First for Pharma Jobs Across the Globe 2
(Date:11/6/2014)... Insilico Medicine, Inc, a Baltimore-based bioinformatics company focused ... announced a research collaboration with the international leader ... (OTC: CSBR). , "There are many companies utilizing ... Oncology,s TumorGraft technology is unique in a way ... generating vast amounts of valuable data. Our bioinformatic ...
(Date:11/4/2014)... the right amount of death at the right time ... to new research that could help in understanding animal ... , In a paper in the journal Trends ... and European colleagues conclude that the kind of positive ... of individuals, or mortality, depends on the size and ...
(Date:11/4/2014)... of Madagascar,s 101 species of lemurs are threatened with ... rainforests they call home. A new study by Rice ... on rainforest tree populations, which raises concerns about the ... rich biodiversity. , A large proportion of trees in ... in turn disperse the seeds of their fruit trees ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2When less is more: Death in moderation boosts population density in nature 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3
... Rochester Medical Center have uncovered a promising drug therapy ... Batten disease a rare neurodegenerative disease that strikes ... to see, reason and move, and ultimately kills them ... the January edition of Experimental Neurology, explains how investigators ...
... to eat at the holidays: Dont take your cues from ... Pole resident eats are a no-no. But you dont have ... University of Florida researchers say. In fact, many ... according to findings from a UF paper published recently in ...
... work better on some children than on others, but judging ... no simple task. Now researchers have developed a new mathematical ... treat children who are abnormally short for a wide range ... access journal BMC Medical Informatics and Decision Making describes a ...
Cached Biology News:Research unveils new hope for deadly childhood disease 2Too much fructose could leave dieters sugar shocked 2Too much fructose could leave dieters sugar shocked 3
... expression vectors, we in-troduced a new concept, namely ... tran-scriptional level at the T7 phage promoter, and ... the plasmid copy number, The main advantage of ... practically all of the outstanding features of the ...
... Anti Nop1p/Fibrillarin (monoclonal) Nop1p/Fibrillarin ... protein of bakers yeast, Saccharomyces cerevisiae ... essential for yeast viability and is ... homologue of Nop1p is fibrillarin (accession ...
... protein crystallography involves using many of the ... The liquid handling requirements are similar to ... crystallography plates have 24 or 48 wells ... For higher throughput, the number of wells ...
... The Reverse-iT™ One-Step Kit is the ... in RT-PCR. It has been specifically ... The Reverse-iT™ One-Step Kit combines ... and ABgene®s Thermoprime Plus DNA Polymerase ...
Biology Products: